The DIA 2024 Global Annual Meeting invites industry, regulators, governments, academics, innovators, and patients to network, problem-solve, and discuss global and local challenges facing the life sciences community. Hosted in San Diego, DIA 2024 will amplify different perspectives while highlighting expertise across the globe to reimagine current processes that better enhance health and well-being.
Join TransCelerate at the following sessions (all times PDT):
- Monday, June 17 at 3:30 p.m.: “Paradigm Shift in Adverse Event Report Management & Sharing: The Case, Need, & Possible Ways Forward,” with Andrew Bate (GSK), Mayur Patel (AstraZeneca), and Phil Tregunno (MHRA).
- Tuesday, June 18 at 3:15 p.m.: “Enhancing Adoption of Innovative Approaches in Clinical Trials,” with Allison Cuff-Shimooka (TransCelerate BioPharma), Michelle Rohrer (Roche), Meghana Chalasani (FDA CDER), Kevin Bugin (FDA CDER), and Ella Balasa (Balasa Consulting).
- Tuesday, June 18 at 3:15 p.m.: “How Will the Increasing Use of Real-World Evidence for Regulatory Decision-Making Impact QA Strategies and GCP Inspections?” with Andrew Gray (Johnson & Johnson), Lee Pai-Scherf (FDA), Abi Seifert (Novartis), L’Oreal Walker (FDA).
- Wednesday, June 19 at 8:00 a.m.: “How Common Data Models Can Address the Challenges in the Use of Clinical Trial and Real-World Data for Evidence Generation“ with Jonathan Chainey (Roche), Davera Gabriel (Evidentli), Jesper Kjaer (Novo Nordisk), and Stacy Tegan (TransCelerate BioPharma).
- Wednesday, June 19 at 4:30 p.m.: “Patient-Centric Approaches in Summaries & Data Return,” with Jean Sposaro (BMS).
- Thursday, June 20 at 9:15 a.m.: “Unleashing Biopharma Potential: Maximizing Consortia Engagement with Strategic Change Management” with John Dobbins (TransCelerate BioPharma), Toni Spears (Sanofi), John Sun (Novartis), and Sarah Tremethick (Roche).